Pure Global
NCT06410092

Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL001 in Patients With Advanced or Metastatic Solid Tumors
Sound Biopharmaceuticals Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
FTL001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sound Biopharmaceuticals Ltd.
Location
Beijing,Chongqing,Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
Jun 05, 2023
End date
Mar 01, 2027
Enrollment
44 participants
Primary outcome

Number of participants with dose-limiting toxicities (DLTs)

Summary

This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability,
 pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced
 and metastatic solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410092
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410092 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sound Biopharmaceuticals Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.